Hikma Pharmaceuticals has agreed to acquire two nasal sprays as well as unit-dose nasal spray manufacturing assets from Insys Therapeutics, the company said. In June 2019, Insys declared bankruptcy and said that it would sell all of its assets. Hikma did not say how much it paid for the naloxone and epinephrine nasal sprays. Insys announced results from a dose … [Read more...] about Hikma acquires naloxone and epinephrine nasal sprays from Insys
News
Perrigo and Endo settle suit over Nascobal nasal spray
Perrigo announced that it has settled a lawsuit filed by Endo Pharmaceuticals in May 2019 that alleged infringement of patents related to Nascobal cyanocobalamin nasal spray which expire in 2024. The terms of the settlement were not disclosed. Perrigo Executive VP and President, Rx Pharmaceuticals Sharon Kochan said, "This settlement is another example of our … [Read more...] about Perrigo and Endo settle suit over Nascobal nasal spray
Third Pole Therapeutics gets US patents for inhaled nitric oxide delivery systems
Third Pole Therapeutics said that it has received two new patents from the US Patent and Trademark Office covering its inhaled nitric oxide (iNO) delivery systems through at least 2038. The patents (No. 10,286,176 and No. 10,328,228) are titled "Systems and Methods for Generating Nitric Oxide" and "Systems and Methods for Ambulatory Generation of Nitric … [Read more...] about Third Pole Therapeutics gets US patents for inhaled nitric oxide delivery systems
Adherium announces deal with Summatix
Inhaler monitoring company Adherium said that it has signed a deal with Summatix (formerly Charm Informatics) to allow data from Adherium's Hailie connected inhaler sensors to be accessed through the Summatix medical data platform. Adherium also announced the launch of a new Hailie app for patients and an updated platform for clinicians. Adherium received OTC … [Read more...] about Adherium announces deal with Summatix
Pulmatrix gets another US patent for iSPERSE formulations
The United States Patent and Trademark Office has granted US patent No. 10376465 ("Monovalent Metal Cation Dry Powders for Inhalation") to Pulmatrix, the company said. The claims cover formulations of Pulmazole inhaled dry powder itraconazole, which is based on Pulmatrix's iSPERSE particle engineering technology. Earlier this year, Pulmatrix announce that it had … [Read more...] about Pulmatrix gets another US patent for iSPERSE formulations
Circassia appoints Jonathan Emms Chief Operating Officer
Circassia Pharmaceuticals has announced the appointment of Jonathan Emms as Chief Operating Officer and as an Executive Director of the Board of Directors. Emms previously served in a number of executive roles at Pfizer, most recently as Chief Commercial Officer, Internal Medicine. The company also said that Senior VP of R&D Rod Hafner will leave the board, … [Read more...] about Circassia appoints Jonathan Emms Chief Operating Officer
Proveris Scientific adds to its Americas and Asia Pacific customer support team
Proveris Scientific has announced an expansion of its Americas and Asia Pacific customer service support team with the hire of Doug Mann as a Field Service Engineer. The company also recently added Stephen McDonald to its European customer support team. Mann, who most recently provided field support at TTP LabTech, joins Senior Field Service Engineer Kevin O'Keefe … [Read more...] about Proveris Scientific adds to its Americas and Asia Pacific customer support team
Merxin says FDA deems its MRX001 blister multidose DPI appropriate for generic Advair
According to generic inhalation device developer Merxin, the FDA has reviewed data for the company's MRX001 blister multidose DPI and suggested that the agency would accept the MRX001 as an AB rated substitutable version of Diskus. The company shared this quote from the FDA's response: “After reviewing your controlled correspondence submitted on May 3, 2019, the … [Read more...] about Merxin says FDA deems its MRX001 blister multidose DPI appropriate for generic Advair
Evoke anticipates resubmitting Gimoti NDA by the end of 2019
Evoke Pharma said that it has received minutes from a July 25, 2019 Type A meeting with the FDA and that the company now plans to resubmit its NDA for Gimoti metoclopramide nasal spray for the treatment of diabetic gastroparesis in the fourth quarter of 2019. The company initially submitted the NDA in June 2018; in April 2019, the agency issued a CRL in response to … [Read more...] about Evoke anticipates resubmitting Gimoti NDA by the end of 2019
Nemera acquires Insight Product Development
Device developer and manufacturer Nemera has announced its acquisition of Insight Product Development, which will become the US office of Nemera's “Insight Innovation Center.” The company's other design center office is located in La Verpillière, France. Insight's capabilities include early stage development of DPIs, MDIs, and connected devices. According to Nemera, … [Read more...] about Nemera acquires Insight Product Development